Signal transducer and activator of transcription protein; Th17, T helper cells that produce interleukin-17; Th1, T helper 1; Th2, T helper 2; Th9, T helper cells that produce interleukin-9; TNFα, Tumor necrosis factor alpha; TSLP, Thymic stromal lymphopoietin; TBXA2, Tromboxane receptor A2; ULABA, Ultra-long-acting beta-agonists; ULAMA, ultra-long-acting muscarinic agonists; WHO, World Health Organization. † The Task Force of Immunopharmacology (TIPCO) within the Immunology Section of EAACI was established in 2017 to connect scientist and clinicians with the different scientific backgrounds-physicians and basic scientists, pharmacologists, computational biologists-with the task of examining recent breakthroughs on basic mechanisms of immune regulation and review their application in current, upcoming, and paradigm-shifting therapeutic approaches for allergy and clinical immunology-related diseases. The different topics for this first position paper, based on comparison of biologicals and small molecule drug therapeutic approaches, were assigned and drafted by authors' subgroups. They were further discussed, developed, and compiled during a meeting in Salerno (February 24-25, 2018) . The position paper draft was thereafter recirculated and critically appraised until the final version was approved by all Task Force Members.
safe and effective therapies for such respiratory diseases is an arduous and expensive process. Antibody-based (biological) therapies are successful in treating certain respiratory conditions not controlled by standard therapies such as severe allergic and refractory eosinophilic severe asthma, while in other inflammatory respiratory diseases, such as COPD, biologicals are having a more limited impact. Small molecule drug (SMD)-based therapies represent an active field in pharmaceutical research and development. SMDs expand biologicals' therapeutic targets by reaching the intracellular compartment by delivery as either an oral or topically based formulation, offering both convenience and lower costs. Aim of this review was to compare and contrast the distinct pharmacological properties and clinical applications of SMDs-and antibody-based treatment strategies, their limitations and challenges, in order to highlight how they should be integrated for their optimal utilization and to fill the critical gaps in current treatment for these chronic inflammatory respiratory diseases.
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| INTRODUCTION
According to the World Health Organization (WHO), chronic inflammatory diseases are approaching pandemic proportions.
1 With regard to respiratory diseases, bronchial asthma is the most common chronic, non-communicable disease among children and affects 358 million people worldwide with 49 millions solely in Europe. [2] [3] [4] [5] In 2016, the global prevalence of chronic obstructive pulmonary disease (COPD) was 251 million, placing it as the fourth leading cause of death worldwide. 1 The economic cost of asthma across Europe is estimated at €17 billion per year with an annual productivity loss estimated at €9.8 billion. 6 In addition, the total direct costs for COPD are estimated at about 3.4% of the total healthcare budgetapproximately 38.6 billion Euros. 4 Despite this health crisis, current development of new safe and effective therapies for respiratory diseases takes longer, costs more, and is less successful than for other diseases. 7 In the past decade, high-throughput technology and systems biology have rapidly expanded our understanding of the molecular networks underlying airway disease pathogenesis, aiding the discovery and better definition of targetable pathways. In this scenario, identification of specific phenotypic and endotypic determinants of asthma and COPD is one of our major research challenges. We should aim for targeted therapies that fulfill the ambitious goal of modifying the natural course of disease rather than symptom control, yet remaining safe, available, and affordable, especially for lowincome patients.
Along with the success of biologicals for treating allergic-and other immune-mediated conditions-such as severe asthma, systemic lupus erythematosus, rheumatoid arthritis, and cancer-small molecule drug (SMD)-based therapies represent an active field in drug research and development and remain highly sought-after in immune-mediated diseases. 8, 9 These two drug classes have powerful and distinct biochemical, pharmacological, and clinically effective characteristics as well as features limiting their therapeutic performance and they can be used together to create powerful combinations. 10 The main objective of this position paper from the EAACI Task Force on Immunopharmacology † is to compare and contrast the major biologicals and SMD-based therapeutic strategies currently available or under clinical investigation for asthma and/or COPD in order to highlight how their distinctive pharmacological and clinical characteristics apply to therapeutic options. In particular, upon a brief review of the main features of the two diseases, we compare the distinct pharmacological properties and clinical applications of SMD-and biological-based therapeutic strategies-with their specific strengths and limitations-and provide an up-to-date list of compounds and online sources. 10 Reviewing pharmacological and clinical data side by side reveals ROTH-WALTER ET AL.
| 433 common unmet needs for these two drug classes and highlights potential avenues for expanding their therapeutic applications for these chronic respiratory diseases.
| PHENOTYPES, ENDOTYPES, AN D BIOMARKERS IN ASTHMA AND COPD: UN COVER ING THE COMPLEXITY OF CHRONIC RESPIRATORY D ISEASES CALLS FOR MULTIPLE AND TARGETED THERAPEUTIC APPROACHES
Asthma and COPD are both chronic inflammatory airway diseases, though their natural history, pathophysiology, and clinical features differ considerably (Tables 1 and 2 No single biomarker is sufficiently specific and sensitive to predict the progression of COPD, the occurrence of exacerbations, the evolution under treatment, or the mortality risk. 23 The most widely (Table 3) .
The majority of patients with asthma achieve their therapeutic goals with the current guideline-based therapy. 25 Biologicals and SMDs differ not only in terms of size, but also in how they are produced, how they behave, their mode of action in the body, and their suitability for certain formulations (Table 4) . 32 Biologicals are large molecular weight therapeutic agents that are synthesized by living organisms and directed against determinants such as cytokines, their receptors, or other different specific targets. 33 Biologicals can be monoclonal antibodies (mAbs) or recombinant proteins such as soluble receptors for specific cytokines or mutated cytokines able to bind the receptor without activation.
SMDs are defined as single molecules with a molecular weight <900
Dalton. Their structure is simple, well-defined, and independent of the manufacturing process used to create them. Any modification is well characterized, and SMDs are mostly produced by chemical synthesis; therefore, identical copies can be made having well-defined physicochemical properties. 34 Conversely, the development of biologicals requires relatively complex processes with higher associated monetary costs than SMDs, 35 as the production of biologicals undergoes multiple scaling-up, purification, and quality control steps. 33 The SMDs are generally less specific than therapeutic biologicals, although this limited specificity might be potentially advantageous as it may allow inhibition of multiple, clinically relevant signaling pathways at non-toxic levels. Conversely, the capacity of biologicals to target single determinants ensures high specificity and are therefore ideal for "personalized" or "tailored" medicine as evidenced in oncology. (Table S1 ).
Most new-generation topical inhaled glucocorticoids are in fact characterized by low systemic bioavailability, high clearance, local activation, and/or strong tendency to form lipid conjugates, resulting in high drug concentrations in lower airway epithelial cells and slow drug redistribution. 37 These features are shared by the highly lipophilic long-acting beta-agonists (LABA) and muscarinic antago- 
| Nobody is perfect: Limitations and critical issues related to biologicals and SMDs
The relatively lower specificity of SMDs compared to biologicals carries an increased risk of toxicity. Currently, AEs to SMDs due to offtarget effects are increasingly identified in the early stages of drug development by computational analysis. 41 However, toxicity has significantly hampered the progression of many MAP-kinase, phosphoinositide 3-kinase (PI3K)δ (or γ), and JAK inhibitors beyond phase 2 clinical trials in COPD (Table 6) | 435 pathways 44 and also in this case, lack of patient selection. 8 The inhaled route for these SMDs may deliver an effective local concentration with much reduced systemic exposure and AEs. 45 The 58 Consequently, these drugs were often prescribed by default to patients in whom other therapies proved ineffective with subsequent therapeutic failure. 59 This inadequate approach led to the termination of several Additional biologicals (Table 5) (Table 6 ).
Also in this case, rather than inferring, on these bases, a lack of pathogenic significance and/or targetability of these molecules and pathways, the efficacy of the biologicals and SMD-based strategies that failed in preclinical or clinical studies will need to be revisited The heterogeneity of asthma and COPD pathophysiology lends itself to the use of drug combinations to target different disease determinants. For severe asthma (step 5 GINA), a targeted biological therapy is given as an add-on with conventional SMD therapy with significant glucocorticoid-sparing effects. 78 The advent of new biologicals and SMDs should hasten new opportunities for testing associations of these drugs classes, taking advantage of the relative strengths of each approach, in order to improve overall therapeutic efficacy.
To date, no double-blind controlled trial studying the combination of biologicals in severe asthma has been published due to the high cost of each drug. Nevertheless, the effect of their combined administration remains to be investigated. There is a programmed study involving dupilumab and REGN3500, a mAb against IL-33, and a combination of the two drugs for asthma (NCT03112577).
Studies on association of SMDs are limited but promising: a double-blind controlled trial of patients with moderate-to-severe asthma found that co-administration of roflumilast and montelukast was superior to montelukast alone in improving lung function and disease control. 79 Combining synergistic bronchodilator and anti-inflammatory properties, dual PDE3/4 inhibitors yielded promising results in phase 2 studies of both asthma and COPD. 80 This inhaled preclinically, is that the addition of a biological to an SMD could lower the latter's effective dosage, reducing toxicity while preserving efficacy. 85, 86 Given the large heterogeneity of asthma and especially of COPD Cost-effectiveness calculated as the sum of immediate and longterm risk reductions academia and industry, from biomarker identification to integrated disease approaches. 89, 90 The requirement for adequate biomarkers and targeted therapies needs to be effectively addressed by both biologicals and SMD strategies in order to deliver "the right drug to the right patient" (Table 7) .
On the "right patient" side of this connection, recent meta-analysis of anti-IL-5 therapies for asthma 55 suggests that more basic/translational research and bioinformatics analyses need to be devoted to the identification of outcome-specific biomarkers. These will probably be composite biomarkers, with higher sensitivity/specificity than single markers 91 to assess multiple parameters, such as treatment response, optimal duration and long-term effects of treatment, risk of relapse on withdrawal and biomarkers for children <12 years. It is critical to get a deeper mechanistic understanding of COPD and non-T2 asthma endotypes, to enable endotypic discrimination and the development of targeted therapies for these large, heterogeneous patient populations that lack any disease-modifying therapies.
The adoption of appropriate biomarkers, as used for trials of biologicals, also in studies evaluating SMDs will introduce a phenotype/endotype-driven patient selection for this class of drugs as wellultimately to "dare to compare" biologicals and SMDs, for example, anti-IL-5 with CRTH2 antagonists.
On the "right drug" side, it is intrinsically difficult to reconcile a single-target approach-ideal for high specificity and low side effects patients with COPD or severe asthma, is keenly needed. 92 Together with formulation for the inhaled route, it will enable the delivery of safe and effective inhibitors with powerful anti-inflammatory properties that circumvent systemic side effects. 9, 44 Looking ahead, preclinical studies on single inhibitors targeting multiple molecules are being undertaken for both biologicals and SMDs with the dual IL-4/IL-13 blocking mAbs against their receptor subunit IL-4Rα (dupilumab , Table 5 ), with bi-specific antibodies (eg, dual antagonists for IL-4/IL-13, CXCR3/CCR6, and CCR3/CD300a), [93] [94] [95] and with multi-target receptor tyrosine kinase inhibitors, so far developed for anti-angiogenic treatment in lung cancer. 96 At present, however, we should also learn from the preclinical | 445
